Is the business good?
How good a business is NTLA?
Intellia Therapeutics, Inc. keeps −637% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
−637%
Operating margin · Biotechnology median −72% · 12 months to Q1 2026
- Share count, year on year
- +14%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 546%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −236% |
| FY2021 | −810% |
| FY2022 | −879% |
| FY2023 | −1421% |
| FY2024 | −923% |
| FY2025 | −652% |
Details›
- Operating margin12 months to Q1 2026
- −637%
- Net margin12 months to Q1 2026
- −597%
- Free cash flow margin
- −550%
- R&D as % of revenue
- 546%
- Revenue, trailing twelve months
- $66M
- Free cash flow, trailing twelve months
- −$364M
- Net income, trailing twelve months
- −$395M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.